RxDoctor Payments Data

Marie le, MD

Transplant Surgery · Bronx, NYNPI 1740402023

Payments from drug & device makers

What this record shows

9 manufacturers reported payments, led by Intuitive Surgical at 55.4% of the total. Reporting peaked in 2023 at $739 and has fallen 52.5% since, to $351 in 2025. That places this record below the midpoint for transplant surgery clinicians in NY, where the typical reported total is $1,271.

$1,407in general payments, 2019–2025

Across 17 payments — averaging $82.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$780
  • AbbVie$179
  • Paragonix Technologies, Inc.$164
  • Sanofi-aventis U.S. LLC$146
  • Medtronic$48
  • Calliditas Therapeutics US Inc.$28
  • plus $63 from 3 others
$318in research payments, 2019–2025

Across 2 payments — averaging $159.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Transmedics, Inc.$318

What the payments were for

  • Travel & lodging$73952%
  • Food & beverage$66848%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,407 in reported general payments places this provider in the 50th percentile of 72 transplant surgery providers in New York.

See all transplant surgery providers in New York

Medicare billing

Part B allowed, 2024
$70,800
Medicare patients
44
Services billed
109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atovaquone15$4,167
Valganciclovir Hcl18$2,410
Famotidine30$85
Tamsulosin Hcl16$67
Easy Touch Alcohol Prep PadsAlcohol Antiseptic Pads11$39
Atorvastatin Calcium13$24

Paid to pharmacies, not to this prescriber.

Other transplant surgery in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →